Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States.
Cronos Group stock last closed at $2.64, up 3.13% from the previous day, and has increased 30.69% in one year. It has overperformed other stocks in the Drug Manufacturers - Specialty & Generic industry by 0.61 percentage points. Cronos Group stock is currently +65% from its 52-week low of $1.60, and -23.03% from its 52-week high of $3.43.
As of Feb 6, 2026, there are 382.89M shares of CRON outstanding. The market cap of CRON is $1.01B. In the last 24 hours, 937,000 CRON shares were traded.
You need a brokerage account to access the NASDAQ market and buy CRON shares.
In our opinion, eToro is the best stock brokerage. eToro gives you:
Get $10 towards your stock purchase by opening an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've chosen the right brokerage, the next step is to fill out some personal information so you are able to invest in CRON stock today.
Now that you've opened your account on the best stock app for beginners, you can securely and quickly fund your account:
Watch this video walkthrough if you need help depositing funds into your investment account.
After you have decided on the best place to buy Cronos Group stock, it's absolutely critical to evaluate their stock prior to buying, so you can wrap your head around the risk as well as the opportunity.
WallStreetZen was designed to help everyday investors do better fundamental analysis in less time.
You can see all of the due diligence checks on CRON's stock page.
You can use many financial metrics, analyses, models, and charts to gauge CRON's true value.
Using relative valuations ratios:
You can access additional valuation analysis on CRON's stock here.
You can dive deeper into what analysts are projecting on the Cronos Group stock forecast page.
Last year, CRON revenue was $132.36M. In the last five year, CRON's revenue has grown by 29.05% per year. This was faster than the Drug Manufacturers - Specialty & Generic industry average of 7.78%.
Learn more about CRON's earnings and revenue performance here.
Over the last year, insiders at CRON have sold more shares than they have bought.
Michael Ryan Gorenstein, Chairman Chief Executive Officer and President of CRON, was the latest CRON insider to sell. They sold $212,556.54 worth of CRON shares on Dec 13, 2025.
Get more info about who owns CRON stock here.
No, Cronos Group doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
There are two primary options:
Hit the Open Trade button and your broker will place the order.
If you need more assistance investing in stocks on eToro, click the how to video below:
Now that you own some CRON stock, you'll want to stay up-to-date on your company.
Put CRON on a watchlist to track the most important metrics related to your CRON stock.
To reiterate, here are the 6 steps you need to take to buy Cronos Group stock right now:
If you need a place to buy stocks, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to monitor your new investment in Cronos Group, get started below.